Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 5/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163640 | 0.90 | EGFR (0.59) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL2164111 | 0.89 | SLC2A1 (0.55) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL2164310 | 0.89 | EGFR (0.58) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL2163779 | 0.88 | KDR (0.61) | EGFRKDRLCKFBP1SRC | |
| SCHEMBL2164238 | 0.88 | FBP1 (0.67) | EGFRKDRLCKFBP1SRC | |
| SCHEMBL2164101 | 0.88 | FBP1 (0.67) | EGFRKDREPHB2FBP1SRC | |
| SCHEMBL2163647 | 0.87 | EGFR (0.56) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL2165634 | 0.85 | EGFR (0.54) | EGFRKDRLCKSRCERBB2 | |
| SCHEMBL2164600 | 0.85 | EGFR (0.66) | EGFRKDRFBP1ERBB2ERBB4 | |
| SCHEMBL2164488 | 0.84 | SRC (0.51) | EGFRKDRLCKFBP1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | claimed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | claimed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | claimed |
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | disclosed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | disclosed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | KDR, FLT1, FLT4 | EGFR 8/4885KDR 1/4885RET 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.